Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
ERBB2 and HSP90AA1	erb-b2 receptor tyrosine kinase 2	heat shock protein 90kDa alpha (cytosolic), class A member 1	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Axon guidance PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Sema4D in semaphorin signaling Sema4D induced cell migration and growth-cone collapse Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	HSF1 activation Regulatory RNA pathways Signaling by EGFRvIII in Cancer Regulation of PLK1 Activity at G2/M Transition Influenza Life Cycle Influenza Viral RNA Transcription and Replication Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Uptake and actions of bacterial toxins EPH-Ephrin signaling Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation Fcgamma receptor (FCGR) dependent phagocytosis Recruitment of mitotic centrosome proteins and complexes Regulation of actin dynamics for phagocytic cup formation vRNP Assembly Influenza Infection Signaling by ERBB2 Signaling by VEGF Signaling by EGFR in Cancer Sema3A PAK dependent Axon repulsion Mitotic G2-G2/M phases Uptake and function of diphtheria toxin PIWI-interacting RNA (piRNA) biogenesis Organelle biogenesis and maintenance Axon guidance Attenuation phase G2/M Transition VEGFA-VEGFR2 Pathway HSF1-dependent transactivation EPHA-mediated growth cone collapse Metabolism of nitric oxide VEGFR2 mediated vascular permeability Loss of Nlp from mitotic centrosomes Scavenging by Class F Receptors eNOS activation and regulation Innate Immune System Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Assembly of the primary cilium Cellular response to heat stress Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic eNOS activation Loss of proteins required for interphase microtubule organizationÂ from the centrosome Centrosome maturation Constitutive Signaling by EGFRvIII	Trastuzumab Lapatinib ado-trastuzumab emtansine Pertuzumab Afatinib	Rifabutin Nedocromil 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine Geldanamycin 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid 17-Dmag 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine Adenosine-5\'-Diphosphate 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
ERBB2 and SOS1	erb-b2 receptor tyrosine kinase 2	son of sevenless homolog 1 (Drosophila)	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Axon guidance PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Sema4D in semaphorin signaling Sema4D induced cell migration and growth-cone collapse Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease SHC-mediated cascade FCERI mediated MAPK activation Platelet Aggregation (Plug Formation) Signaling by EGFRvIII in Cancer SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Regulation of KIT signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling Gastrin-CREB signalling pathway via PKC and MAPK SOS-mediated signalling SHC-mediated signalling Signaling by PDGF DAP12 interactions SHC-related events triggered by IGF1R GRB2 events in EGFR signaling Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins SHC1 events in ERBB4 signaling Signalling to RAS Downstream signal transduction Signaling by Rho GTPases Signaling by FGFR mutants Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System Signalling to ERKs Axon guidance IRS-mediated signalling IGF1R signaling cascade Rho GTPase cycle IRS-related events triggered by IGF1R EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling Activation of Rac Downstream signaling of activated FGFR G alpha (12/13) signalling events NCAM signaling for neurite out-growth Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cell death signalling via NRAGE, NRIF and NADE SOS-mediated signalling SHC-mediated signalling Integrin alphaIIb beta3 signaling p75 NTR receptor-mediated signalling Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane GRB2:SOS provides linkage to MAPK signaling for Integrins SHC-related events Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR SHC1 events in EGFR signaling FRS2-mediated cascade IRS-mediated signalling Signal attenuation NRAGE signals death through JNK Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling FCERI mediated Ca+2 mobilization Constitutive Signaling by EGFRvIII Signaling by Robo receptor	Trastuzumab Lapatinib ado-trastuzumab emtansine Pertuzumab Afatinib
ERBB4 and NRG1	erb-b2 receptor tyrosine kinase 4	neuregulin 1		Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Nuclear signaling by ERBB4 SHC1 events in ERBB4 signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System
ERBB4 and SHC1	erb-b2 receptor tyrosine kinase 4	SHC (Src homology 2 domain containing) transforming protein 1		Signaling by GPCR Signaling by EGFRvIII in Cancer Platelet Aggregation (Plug Formation) SHC1 events in ERBB2 signaling IRE1alpha activates chaperones Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling SHC-mediated signalling G-protein beta:gamma signalling SHC-related events triggered by IGF1R Signaling by ERBB4 Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins GPCR downstream signaling SHC1 events in ERBB4 signaling Signalling to RAS Signaling by EGFR in Cancer Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Signalling to ERKs IGF1R signaling cascade XBP1(S) activates chaperone genes G beta:gamma signalling through PI3Kgamma Unfolded Protein Response (UPR) Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade SHC-mediated signalling Integrin alphaIIb beta3 signaling Signaling by Ligand-Responsive EGFR Variants in Cancer Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane SHC-related events Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall SHC1 events in EGFR signaling Signal attenuation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling GPVI-mediated activation cascade Constitutive Signaling by EGFRvIII SHC activation
ESR1 and FOXO3	estrogen receptor 1	forkhead box O3	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Signaling by NODAL Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR AKT phosphorylates targets in the nucleus Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
ESR1 and SHC1	estrogen receptor 1	SHC (Src homology 2 domain containing) transforming protein 1	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Signaling by GPCR Signaling by EGFRvIII in Cancer Platelet Aggregation (Plug Formation) SHC1 events in ERBB2 signaling IRE1alpha activates chaperones Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling SHC-mediated signalling G-protein beta:gamma signalling SHC-related events triggered by IGF1R Signaling by ERBB4 Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins GPCR downstream signaling SHC1 events in ERBB4 signaling Signalling to RAS Signaling by EGFR in Cancer Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Signalling to ERKs IGF1R signaling cascade XBP1(S) activates chaperone genes G beta:gamma signalling through PI3Kgamma Unfolded Protein Response (UPR) Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade SHC-mediated signalling Integrin alphaIIb beta3 signaling Signaling by Ligand-Responsive EGFR Variants in Cancer Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane SHC-related events Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall SHC1 events in EGFR signaling Signal attenuation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling GPVI-mediated activation cascade Constitutive Signaling by EGFRvIII SHC activation	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
ESR1 and SKIL	estrogen receptor 1	SKI-like proto-oncogene	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity TGFBR1 LBD Mutants in Cancer Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Loss of Function of TGFBR1 in Cancer Generic Transcription Pathway Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
ESR1 and MDM2	estrogen receptor 1	MDM2 proto-oncogene, E3 ubiquitin protein ligase	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade Stabilization of p53 Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Transmission across Chemical Synapses PIP3 activates AKT signaling Oncogene Induced Senescence p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Signalling by NGF Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Trafficking of AMPA receptors Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR Oxidative Stress Induced Senescence Cell Cycle Checkpoints Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE	Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
ESR1 and PTEN	estrogen receptor 1	phosphatase and tensin homolog	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Signaling by the B Cell Receptor (BCR) Downstream TCR signaling Metabolism of lipids and lipoproteins Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Synthesis of PIPs at the plasma membrane Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Synthesis of IP3 and IP4 in the cytosol PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Phospholipid metabolism PI Metabolism Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Negative regulation of the PI3K/AKT network Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Inositol phosphate metabolism PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR TCR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
ESR1 and SMAD4	estrogen receptor 1	SMAD family member 4	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
ESR1 and SMAD2	estrogen receptor 1	SMAD family member 2	Nuclear signaling by ERBB4 Generic Transcription Pathway Nuclear Receptor transcription pathway Signaling by ERBB4	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Diethylstilbestrol Chlorotrianisene Conjugated Estrogens Etonogestrel Desogestrel Levonorgestrel Progesterone Raloxifene Toremifene Medroxyprogesterone Estrone Tamoxifen Estradiol Ethynodiol Diacetate Clomifene Dienestrol Fulvestrant Norgestimate Ethinyl Estradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Allylestrenol Genistein Compound 19 Compound 18 Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estropipate Quinestrol Ospemifene 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL RALOXIFENE CORE
EWSR1 and SMAD4	EWS RNA-binding protein 1	SMAD family member 4		Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by BMP Transcriptional regulation of pluripotent stem cells Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
BPTF and SMAD2	bromodomain PHD finger transcription factor	SMAD family member 2		Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
FGF1 and FGFR3	fibroblast growth factor 1 (acidic)	fibroblast growth factor receptor 3	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade Signaling by activated point mutants of FGFR1 Signaling by FGFR1 mutants PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Signaling by FGFR3 mutants Downstream signal transduction Signaling by activated point mutants of FGFR3 Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling FGFR1b ligand binding and activation Downstream signaling of activated FGFR FGFR3b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR ligand binding and activation FGFR2b ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane FGFR3 ligand binding and activation Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR FRS2-mediated cascade FGFR2 ligand binding and activation IRS-mediated signalling FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by FGFR in disease Signaling by FGFR3 mutants Signaling by activated point mutants of FGFR3 Signaling by FGFR mutants t(4;14) translocations of FGFR3	Pentosan Polysulfate Amlexanox Sucrose Octasulfate Formic Acid O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine Naphthalene Trisulfonate Pazopanib 5-AMINO-NAPHTALENE-2-MONOSULFONATE
FGF1 and FGFR2	fibroblast growth factor 1 (acidic)	fibroblast growth factor receptor 2	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade Signaling by activated point mutants of FGFR1 Signaling by FGFR1 mutants PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Signaling by FGFR3 mutants Downstream signal transduction Signaling by activated point mutants of FGFR3 Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling FGFR1b ligand binding and activation Downstream signaling of activated FGFR FGFR3b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR ligand binding and activation FGFR2b ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane FGFR3 ligand binding and activation Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR FRS2-mediated cascade FGFR2 ligand binding and activation IRS-mediated signalling FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by FGFR2 amplification mutants Signaling by FGFR2 mutants Signaling by FGFR in disease Signaling by FGFR mutants Activated point mutants of FGFR2	Pentosan Polysulfate Amlexanox Sucrose Octasulfate Formic Acid O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine Naphthalene Trisulfonate Pazopanib 5-AMINO-NAPHTALENE-2-MONOSULFONATE	Palifermin Thalidomide SU4984 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Regorafenib Ponatinib
FGF2 and FGFR3	fibroblast growth factor 2 (basic)	fibroblast growth factor receptor 3	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade Signaling by activated point mutants of FGFR1 Signaling by FGFR1 mutants PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Syndecan interactions Signaling by EGFR Signaling by FGFR3 mutants Downstream signal transduction Signaling by activated point mutants of FGFR3 Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R Transcriptional regulation of pluripotent stem cells PI3K events in ERBB2 signaling FGFR1b ligand binding and activation Downstream signaling of activated FGFR FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR ligand binding and activation POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Non-integrin membrane-ECM interactions FGFR3 ligand binding and activation Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR FGFR2 ligand binding and activation FRS2-mediated cascade IRS-mediated signalling FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by FGFR in disease Signaling by FGFR3 mutants Signaling by activated point mutants of FGFR3 Signaling by FGFR mutants t(4;14) translocations of FGFR3	Sucralfate Pentosan Polysulfate Sirolimus 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
FGF3 and FGFR4	fibroblast growth factor 3	fibroblast growth factor receptor 4	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Phospholipase C-mediated cascade SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR1b ligand binding and activation FGFR ligand binding and activation FGFR2b ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR IRS-mediated signalling FGFR2 ligand binding and activation FRS2-mediated cascade FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Signaling by FGFR4 mutants PI-3K cascade PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer betaKlotho-mediated ligand binding Signaling by FGFR Klotho-mediated ligand binding FRS2-mediated cascade IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade		Palifermin Ponatinib
FGF4 and FGFR4	fibroblast growth factor 4	fibroblast growth factor receptor 4	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade Signaling by activated point mutants of FGFR1 Signaling by FGFR1 mutants PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Signaling by FGFR3 mutants Downstream signal transduction Signaling by activated point mutants of FGFR3 Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane FGFR3 ligand binding and activation Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR FGFR2 ligand binding and activation FRS2-mediated cascade IRS-mediated signalling FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Signaling by FGFR4 mutants PI-3K cascade PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer betaKlotho-mediated ligand binding Signaling by FGFR Klotho-mediated ligand binding FRS2-mediated cascade IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Pentosan Polysulfate	Palifermin Ponatinib
FGF6 and FGFR4	fibroblast growth factor 6	fibroblast growth factor receptor 4	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade Signaling by activated point mutants of FGFR1 Signaling by FGFR1 mutants PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR FGFR2 ligand binding and activation FRS2-mediated cascade IRS-mediated signalling FGFR1 ligand binding and activation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Signaling by FGFR4 mutants PI-3K cascade PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 FGFR4 ligand binding and activation Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer betaKlotho-mediated ligand binding Signaling by FGFR Klotho-mediated ligand binding FRS2-mediated cascade IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade		Palifermin Ponatinib
FGF7 and FGFR3	fibroblast growth factor 7	fibroblast growth factor receptor 3	Signaling by the B Cell Receptor (BCR) Phospholipase C-mediated cascade Signaling by FGFR in disease SHC-mediated cascade Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Signaling by FGFR2 mutants DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade PI3K Cascade Negative regulation of FGFR signaling Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer Activated point mutants of FGFR2 PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by FGFR mutants Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R PI3K events in ERBB2 signaling Downstream signaling of activated FGFR FGFR ligand binding and activation FGFR2b ligand binding and activation Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR IRS-mediated signalling FGFR2 ligand binding and activation FRS2-mediated cascade Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade	Signaling by FGFR in disease Signaling by FGFR3 mutants Signaling by activated point mutants of FGFR3 Signaling by FGFR mutants t(4;14) translocations of FGFR3

Search Results for: Cancer